This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients

This study has been completed.
Information provided by:
Göteborg University Identifier:
First received: May 15, 2007
Last updated: March 30, 2012
Last verified: March 2012
The study is designed to evaluate effects of NSAIDs on immune activity inside and close to tumor tissue in patients with colorectal cancer.

Condition Intervention Phase
Colorectal Cancer Drug: Indomethacin, celecoxib, esomeprazole Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Preoperative Treatment With NSAID in Colorectal Cancer Patients in Relationship to Tumor Host Reactions

Resource links provided by NLM:

Further study details as provided by Göteborg University:

Primary Outcome Measures:
  • Immune reactivity [ Time Frame: Acute evaluations ]

Enrollment: 28
Study Start Date: December 1998
Study Completion Date: May 2007
Arms Assigned Interventions
Experimental: Drug
Treatment with indomethacin or celecoxib
Drug: Indomethacin, celecoxib, esomeprazole
Sham Comparator: SHAM
Sham treatment
Drug: Indomethacin, celecoxib, esomeprazole

Detailed Description:
Study and control patients are randomized to receive preoperative treatment with indomethacin or celecoxib compared to sham treatment.Tumor biopsies are taken at operation and used for analyses of tumor immunity and gene expression.

Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Colon carcinoma scheduled for curative operation

Exclusion Criteria:

  • Diabetes, steroid medication, liver and kidney impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00473980

Department of Surgery
Göteborg, Sweden, SE 41345
Sponsors and Collaborators
Göteborg University
Principal Investigator: Kent Lundholm, MD, prof Göteborg University
  More Information

Additional Information: Identifier: NCT00473980     History of Changes
Other Study ID Numbers: kl4501122
Study First Received: May 15, 2007
Last Updated: March 30, 2012

Keywords provided by Göteborg University:
Colon carcinoma

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Gout Suppressants processed this record on August 18, 2017